Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Bernhardt G. Zeiher Acquires 10,000 Shares of Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Bernhardt G. Zeiher purchased 10,000 shares of Amylyx Pharmaceuticals stock in a transaction dated Thursday, March 20th. The stock was bought at an average price of $3.70 per share, with a total value of $37,000.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at $37,000. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Amylyx Pharmaceuticals Stock Up 3.6 %

Amylyx Pharmaceuticals stock opened at $3.78 on Tuesday. The stock has a market cap of $334.92 million, a price-to-earnings ratio of -0.99 and a beta of -0.51. The business has a 50-day simple moving average of $3.52 and a 200 day simple moving average of $4.01. Amylyx Pharmaceuticals, Inc. has a 52 week low of $1.58 and a 52 week high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The firm had revenue of ($0.67) million during the quarter. On average, research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Amylyx Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $7.33.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Boxer Capital Management LLC bought a new position in Amylyx Pharmaceuticals in the fourth quarter valued at $6,615,000. Bank of America Corp DE boosted its holdings in shares of Amylyx Pharmaceuticals by 165.9% in the 4th quarter. Bank of America Corp DE now owns 2,426,263 shares of the company’s stock worth $9,171,000 after purchasing an additional 1,513,748 shares in the last quarter. Alpha Wave Global LP bought a new position in shares of Amylyx Pharmaceuticals during the 3rd quarter valued at about $2,169,000. Walleye Capital LLC raised its holdings in shares of Amylyx Pharmaceuticals by 986.5% during the 3rd quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock valued at $2,173,000 after buying an additional 608,874 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its stake in Amylyx Pharmaceuticals by 862.5% in the fourth quarter. Cubist Systematic Strategies LLC now owns 472,397 shares of the company’s stock worth $1,786,000 after buying an additional 423,316 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.